Cited by 619Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesHematopoietic Stem Cell Transplantation

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Open access

Burnett, Alan K., Milligan, Donald, Prentice, Archie G., Goldstone, Anthony H., McMullin, Mary F., Hills, Robert K., Wheatley, Keith·2007·Cancer

DOI 10.1002/cncr.22496

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach. METHODS: Between December 1998 and November 2003, as part of National Cancer Research Institute Acute Myeloid Leukemia 14 Trial, 217 patients, who were deemed unfit for intensive chemotherapy were randomized to receive low‐dose cytarabine (Ara‐C) (20 mg twice daily for 10 days) or hydroxyurea with or without all‐trans retinoic acid (ATRA). RESULTS: Low‐dose ara‐C produced a better remission rate (18% vs 1%; odds ratio [OR], 0.15; 95% confidence interval [95% CI], 0.06–0.37; P = .00006) and better overall survival (OR, 0.60; 95% CI, 0.44–0.81; P = .0009), which was accounted for by the achievement of complete remission (CR) (duration of CR: 80 weeks vs 10 weeks for patients with no CR). Patients who had adverse cytogenetics did not benefit. ATRA had no effect. Toxicity scores or supportive care requirements did not differ between the treatment arms. CONCLUSIONS: Older, less fit patients have a poor outcome, and few trials have been conducted in this patient group. Low‐dose ara‐C treatment was superior to best supportive care and hydroxyurea because it had greater success in achieving CR, and it could represent standard care against which new treatments may be compared in this patient group. [See editorial on pages 000–000, this issue.] Cancer 2007 © 2007 American Cancer Society.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cncr.22496

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
Campos, L., Rouault, J., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J., & Guyotat, D. (1993) · Blood · doi:10.1182/blood.v81.11.3091.3091 · Cited by 783
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608
On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.
Löwenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, C., Peetermans, M. E., Solbu, G., & Suciu, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1268 · Cited by 383
The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly
Menzin, J., Lang, K., Earle, C. C., Kerney, D. L., & Mallick, R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1597 · Cited by 276
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
Tilly, H., Castaigné, S., Bordessoule, D., Casassus, P., Prisé, P. Y. L., Tertian, G., Desablens, B., Henry-Amar, M., & Degos, L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.272 · Cited by 259
A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
Cheson, B. D., Jasperse, D. M., Simon, R. M., & Friedman, M. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.12.1857 · Cited by 210
Small doses of ARA‐C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?
Housset, M., Daniel, M., & Degos, L. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb07297.x · Cited by 189
Response of Preleukemic Syndromes to Continuous Infusion of Low-Dose Cytarabine
Wisch, J. S., Griffin, J. D., & Kufe, D. W. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312293092602 · Cited by 179
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid
Andreeff, M., Jiang, S., Zhang, X., Konopleva, M. Y., Estrov, Z. E., Snell, V., Xie, Z., Okcu, M., Sanchez‐Williams, G., Dong, J., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401573 · Cited by 153
Sexual functioning morbidity among cancer survivors. Current status and future research directions
Andersen, B. L. (1985) · Cancer · doi:10.1002/1097-0142(19850415)55:8 · Cited by 147

Show all 26 references

Sorted by citations

Items 101–200 of 619

Selecting initial treatment of acute myeloid leukaemia in older adults
Podoltsev, N. A., Stahl, M. F., Zeidan, A. M., & Gore, S. D. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.09.005 · Cited by 85
Novel drugs for older patients with acute myeloid leukemia
Bravo, G. M., & Garcia‐Manero, G. (2014) · Leukemia · doi:10.1038/leu.2014.244 · Cited by 82
Acute myeloid leukemia in the elderly: therapeutic options and choice
Webster, J. A., & Pratz, K. W. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1330956 · Cited by 82
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
Sekeres, M. A., Gundacker, H., Lancet, J., Advani, A., Petersdorf, S., Liesveld, J., Mulford, D., Norwood, T., Willman, C. L., Appelbaum, F. R., et al. (2011) · Blood · doi:10.1182/blood-2011-02-337303 · Cited by 80
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
Samra, B., Konopleva, M. Y., Isidori, A., Daver, N. G., & Dinardo, C. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.562558 · Cited by 86
Acute Myeloid Leukemia
O'Donnell, M. R., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Coutre, S. E., Damon, L. E., Foran, J. M., Goorha, S., Maness, L. J., Marcucci, G., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0027 · Cited by 81
Allogeneic Stem-Cell Transplantation in Patients With NPM1-Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial
Röllig, C., Bornhäuser, M., Krämer, M., Thiede, C., Ho, A. D., Krämer, A., Schäfer‐Eckart, K., Wandt, H., Hänel, M., Einsele, H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.4973 · Cited by 79
Applicability of a “Pick a Winner” trial design to acute myeloid leukemia
Hills, R. K., & Burnett, A. K. (2011) · Blood · doi:10.1182/blood-2011-02-337261 · Cited by 79
Self-citation
Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach
Lee, D. J., & Zeidner, J. F. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1678583 · Cited by 78
Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C
Fenaux, P., Gattermann, N., Seymour, J. F., Hellström‐Lindberg, E., Mufti, G. J., Dührsen, U., Gore, S. D., Ramos, F., Beyne‐Rauzy, O., List, A. F., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08082.x · Cited by 76
Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
Richard‐Carpentier, G., & Dinardo, C. D. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719882822 · Cited by 74
Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia
Schiller, G. J., O'Brien, S. M., Pigneux, A., DeAngelo, D. J., Vey, N., Kell, J., Solomon, S. R., Stuart, R. K., Karsten, V., Cahill, A. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2008 · Cited by 74
Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians
Olíva, E. N., Nobile, F., Alimena, G., Ronco, F., Specchia, G., Impera, S. S., Breccia, M., Vincelli, I. D., Carmosino, I., Guglielmo, P., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.036715 · Cited by 72
The Leukemias: A Half-Century of Discovery
Freireich, E. J., Wiernik, P. H., & Steensma, D. P. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1034 · Cited by 79
Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia
Jurcic, J. G., & Rosenblat, T. L. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e126 · Cited by 72
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
Seymour, J. F., Döhner, H., Butrym, A. K., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J. D., Schuh, A. C., Candoni, A., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3803-6 · Cited by 71
Acute myeloid leukemia in older adults
Yanada, M., & Naoe, T. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1137-3 · Cited by 69
Preclinical and Phase I Results of Decitabine in Combination with Midostaurin ( PKC 412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia
Williams, C. B., Kambhampati, S., Fiskus, W. C., Wick, J., Dutreix, C., Ganguly, S., Aljitawi, O. S., Reyes, R., Fleming, A., Abhyankar, S., et al. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1316 · Cited by 68
All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment
Su, M., Alonso, S., Jones, J. W., Yu, J., Kane, M. A., Jones, R. J., & Ghiaur, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127790 · Cited by 68
Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?
Heuser, M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.24 · Cited by 66
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study
for the German-Austrian Acute Myeloid Leukemia Study Group, Schlenk, R. F., Lübbert, M., Benner, A., Lamparter, A., Krauter, J., Herr, W., Martin, H., Salih, H. R., Kündgen, A., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2810-z · Cited by 65
Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs
Zebisch, A., Hatzl, S., Pichler, M., Wölfler, A., & Sill, H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122080 · Cited by 63
Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
Pleyer, L., Stauder, R., Burgstaller, S., Schreder, M., Tinchon, C., Pfeilstöcker, M., Steinkirchner, S., Melchardt, T., Mitrovic, M., Girschikofsky, M., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-32 · Cited by 61
Recent advances in the understanding and treatment of acute myeloid leukemia
Watts, J. M., & Nimer, S. D. (2018) · F1000Research · doi:10.12688/f1000research.14116.1 · Cited by 61
Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
Griffioen, M. S., de Leeuw, D. D., Janssen, J., & Smit, L. (2022) · Cancers · doi:10.3390/cancers14143456 · Cited by 60
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
Raza, A., Jurcic, J. G., Roboz, G. J., Maris, M. B., Stephenson, J. J., Wood, B. L., Feldman, E. J., Galili, N., Grove, L. E., Drachman, J. G., et al. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903050013 · Cited by 61
Changes in the survival of older patients with hematologic malignancies in the early 21st century
Pulte, D. D., Jansen, L., Castro, F. A., & Brenner, H. (2016) · Cancer · doi:10.1002/cncr.30003 · Cited by 61
Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)
Tawfik, B., Sliesoraitis, S., Lyerly, S., Klepin, H. D., Lawrence, J. A., Isom, S. P., Ellis, L. R., Manuel, M., Dralle, S., Berenzon, D. P., et al. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1940-9 · Cited by 59
Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
Kantarjian, H. M., Sekeres, M. A., Ribrag, V., Rousselot, P. H., Garcia‐Manero, G., Jabbour, E. J., Owen, K., Stockman, P. K., & Oliver, S. D. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.03.019 · Cited by 59
Acute Myeloid Leukemia in the Elderly
Dombret, H., Raffoux, E., & Gardin, C. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.013 · Cited by 58
Prognostic Factors in Elderly Patients with AML and the Implications for Treatment
Erba, H. P. (2007) · Hematology · doi:10.1182/asheducation-2007.1.420 · Cited by 58
The Treatment of Elderly Patients With Acute Myeloid Leukemia
Krug, U. O., Büchner, T., Berdel, W. E., & Müller‐Tidow, C. (2011) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2011.0863 · Cited by 58
Randomized trial of two schedules of low‐dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML‐19)
Amadori, S., Suciu, S., Selleslag, D., Stasi, R., Alimena, G., Baila, L., Rizzoli, V., Borlenghi, E., Gaïdano, G., Magro, D., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08095.x · Cited by 58
The role of hypomethylating agents in the treatment of elderly patients with AML
Al‐Ali, H. K., Jaekel, N., & Niederwieser, D. W. (2013) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2013.08.004 · Cited by 58
The DNA methylation landscape of hematological malignancies: an update
Blecua, P., Martinez‐Verbo, L., & Esteller, M. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12744 · Cited by 57
Azacitidine in adult patients with acute myeloid leukemia
Schuh, A. C., Döhner, H., Pleyer, L., Seymour, J. F., Fenaux, P., & Dombret, H. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.05.010 · Cited by 57
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML
Burnett, A. K., Russell, N. H., Culligan, D. J., Cavanagh, J. D., Kell, J., Wheatley, K., Virchis, A., Hills, R. K., & Milligan, D. W. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09165.x · Cited by 56
Self-citation
Gemtuzumab ozogamicin in acute myeloid leukemia revisited
Thol, F. R., & Schlenk, R. F. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.922534 · Cited by 58
Acute myeloid leukemia – strategies and challenges for targeting oncogenic Hedgehog/GLI signaling
Aberger, F., Hutterer, E., Sternberg, C., del Burgo, P. J., & Hartmann, T. N. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0163-4 · Cited by 56
Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia
Salerno, L., Romeo, G., Modica, M. N., Amata, E., Sorrenti, V., Barbagallo, I. A., & Pittalà, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.031 · Cited by 56
Treatment of acute myeloid leukemia
Estey, E. H. (2008) · Haematologica · doi:10.3324/haematol.2008.001263 · Cited by 56
Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Tayari, M. M., Santos, H. G. D., Kwon, D., Bradley, T., Thomassen, A., Chen, C. Y., Dinh, Y. T., Perez, A., Zelent, A., Morey, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4054 · Cited by 53
Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly
Kuendgen, A., & Germing, U. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.09.001 · Cited by 55
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction
Ramos, F., Thépot, S., Pleyer, L., Maurillo, L., Itzykson, R., Bargay, J., Stauder, R., Venditti, A., Seegers, V., Martínez‐Robles, V., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2014.12.013 · Cited by 54
Clinical Results of Hypomethylating Agents in AML Treatment
Cruijsen, M. J., Lübbert, M., Wijermans, P., & Huls, G. A. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm4010001 · Cited by 54
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO‐dependent mechanism
Kelly, K. R., Nawrocki, S. T., Espitia, C. M., Zhang, M., Yang, J. J., Padmanabhan, S., Ecsedy, J., Giles, F. J., & Carew, J. S. (2012) · International Journal of Cancer · doi:10.1002/ijc.27579 · Cited by 53
An ATRActive future for differentiation therapy in AML
Johnson, D. E., & Redner, R. L. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.01.002 · Cited by 53
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
Karp, J. E., Flatten, K. S., Feldman, E. J., Greer, J. M., Loegering, D. A., Ricklis, R. M., Morris, L. E., Ritchie, E. K., Smith, B. D., Ironside, V., et al. (2008) · Blood · doi:10.1182/blood-2008-08-172726 · Cited by 53
The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
Fredly, H., Ersvær, E., Kittang, A. O., Tsykunova, G., Gjertsen, B. T., & Bruserud, Ø. (2013) · Clinical Epigenetics · doi:10.1186/1868-7083-5-13 · Cited by 53
Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades
Kantarjian, H. M., Short, N. J., Fathi, A. T., Marcucci, G., Ravandi, F., Tallman, M. S., Wang, E. S., & Wei, A. H. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.05.016 · Cited by 56
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy
Sasaki, K., Kadia, T. M., Begna, K. H., Dinardo, C. D., Borthakur, G. M., Short, N. J., Jain, N., Daver, N. G., Jabbour, E. J., Garcia‐Manero, G., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26395 · Cited by 52
Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients
van der Helm, L. H., Scheepers, E. R. M., Veeger, N. J. G. M., Daenen, S. M. G. J., Mulder, A. B., van den Berg, E., Vellenga, E., & Huls, G. A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-29 · Cited by 52
The cure of leukemia through the optimist's prism
Kantarjian, H. M., Jain, N., Garcia‐Manero, G., Welch, M. A., Ravandi, F., Wierda, W. G., & Jabbour, E. J. (2021) · Cancer · doi:10.1002/cncr.33933 · Cited by 54
NOTCH2 mutations in marginal zone lymphoma
Trøen, G., Wlodarska, I., Warsame, A. A., Hernández‐Llodrà, S., Wolf-Peeters, C. D., & Delabie, J. (2008) · Haematologica · doi:10.3324/haematol.11635 · Cited by 52
Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly
Klepin, H. D. (2015) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2015.08.010 · Cited by 53
The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine
Nawrocki, S. T., Kelly, K. R., Smith, P. G., Keaton, M., Carraway, H. E., Sekeres, M. A., Maciejewski, J. P., & Carew, J. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1960 · Cited by 51
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C
Corsetti, M. T., Salvi, F., Perticone, S., Baraldi, A., Paoli, L. D., Gatto, S., Pietrasanta, D., Pini, M., Primon, V., Zallio, F., et al. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.02.021 · Cited by 49
Targeted Alpha-Particle Therapy for Hematologic Malignancies
Jurcic, J. G. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.09.002 · Cited by 50
Incorporation of Gemcitabine and Cytarabine into DNA by DNA Polymerase β and Ligase III/XRCC1
Gowda, A. S. P., Polizzi, J. M., Eckert, K. A., & Spratt, T. E. (2010) · Biochemistry · doi:10.1021/bi100200c · Cited by 48
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia
Dennis, M., Russell, N. H., Hills, R. K., Hemmaway, C. J., Panoskaltsis, N., McMullin, M., Kjeldsen, L., Dignum, H., Thomas, I., Clark, R. E., et al. (2015) · Blood · doi:10.1182/blood-2014-10-608117 · Cited by 48
Self-citation
Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network
Bories, P., Bertoli, S., Bérard, E., Laurent, J., Duchayne, É., Sarry, A., Delabesse, É., Beyne‐Rauzy, O., Huguet, F., & Récher, C. (2014) · American Journal of Hematology · doi:10.1002/ajh.23848 · Cited by 48
New drugs creating new challenges in acute myeloid leukemia
Tiong, I. S., & Wei, A. H. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22750 · Cited by 50
Arsenic trioxide and low‐dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia
Roboz, G. J., Ritchie, E. K., Curcio, T. J., Provenzano, J. L., Carlin, R. F., Samuel, M., Wittenberg, B., Mazumdar, M., Christos, P. J., Mathew, S., et al. (2008) · Cancer · doi:10.1002/cncr.23855 · Cited by 48
Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation
van Gils, N., Verhagen, H. J. M. P., & Smit, L. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.04.007 · Cited by 49
Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
Schliemann, C., Gutbrodt, K. L., Kerkhoff, A., Pohlen, M., Wiebe, S., Silling, G., Angenendt, L., Keßler, T., Mesters, R. M., Giovannoni, L., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0179 · Cited by 47
Contributions of authors
Ender, S. A., Machner, A., Pap, G., Hubbe, J., Graßhoff, H., & Hw, N. (2007) · Acta Orthopaedica · doi:10.1080/17453670710014301 · Cited by 48
Treating the Elderly Patient with Acute Myelogenous Leukemia
Luger, S. M. (2010) · Hematology · doi:10.1182/asheducation-2010.1.62 · Cited by 47
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes
Lin, P., Ren, Y., Yan, X., Luo, Y., Zhang, H., Kesarwani, M., Bu, J., Zhan, D., Zhou, Y., Tang, Y., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.197749 · Cited by 47
Diketopyrrolopyrrole-Based Photosensitizers Conjugated with Chemotherapeutic Agents for Multimodal Tumor Therapy
Cai, Y., Liang, P., Tang, Q., Si, W., Chen, P., Zhang, Q., & Dong, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b09025 · Cited by 46
Progress in Acute Myeloid Leukemia
Kadia, T. M., Ravandi, F., O'Brien, S. M., Cortes, J. E., & Kantarjian, H. M. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.08.006 · Cited by 47
Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models
Walter, R. B., & Estey, E. H. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100679 · Cited by 45
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186
Macdonald, D. A., Assouline, S. E., Brandwein, J. M., Kamel‐Reid, S., Eisenhauer, E. A., Couban, S., Caplan, S. N., Foo, A. H., Walsh, W., & Leber, B. F. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.737917 · Cited by 45
Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias
Leone, G. G. M., D’Alò, F., Zardo, G., Voso, M. T., & Nervi, C. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708784534947 · Cited by 46
A randomized, open‐label, phase I/II trial to investigate the maximum tolerated dose of the P olo‐like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia
Müller‐Tidow, C., Bug, G., Lübbert, M., Krämer, A., Krauter, J., Valent, P., Nachbaur, D., Berdel, W. E., Ottmann, O. G., Fritsch, H., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12518 · Cited by 44
Treatment decisions for elderly patients with haematological malignancies: a dilemma
Peyrade, F., Gastaud, L., Ré, D., Pacquelet, S., & Thyss, A. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70234-6 · Cited by 43
Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
Kantarjian, H. M., Short, N. J., DiNardo, C., Stein, E. M., Daver, N., Perl, A. E., Wang, E. S., Wei, A., & Tallman, M. S. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00270-2 · Cited by 43
Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification
Wetzler, M., Mrózek, K., Kohlschmidt, J., Dombret, H., Döhner, H., Pilorge, S., Krug, U. O., Carroll, A. J., Larson, R. A., Marcucci, G., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.092072 · Cited by 42
Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia
Klepin, H. D. (2014) · Hematology · doi:10.1182/asheducation-2014.1.8 · Cited by 42
Targeting polo-like kinase 1 in acute myeloid leukemia
Brandwein, J. M. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715571077 · Cited by 42
Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy
Acheampong, D. O., Adokoh, C. K., Asante, D.-B., Asiamah, E. A., Barnie, P. A., Bonsu, D. N. O., & Kyei, F. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.100 · Cited by 43
Mechanisms of Hydroxyurea‐Induced Cellular Senescence: An Oxidative Stress Connection?
Kapor, S., Čokić, V. P., & Santibanez, J. F. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/7753857 · Cited by 46
The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome
Burnett, A. K., Hills, R. K., Hunter, A., Milligan, D. W., Kell, J., Wheatley, K., Yin, J. A. L., Mcmullin, M., Cahalin, P. A., Craig, J. I. O., et al. (2011) · Leukemia · doi:10.1038/leu.2011.59 · Cited by 40
Self-citation
Acute myeloid leukemia in the elderly: Conventional and novel treatment approaches
Craig, C. M., & Schiller, G. J. (2008) · Blood Reviews · doi:10.1016/j.blre.2008.03.002 · Cited by 40
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
Pleyer, L., Burgstaller, S., Stauder, R., Girschikofsky, M., Sill, H., Schlick, K., Thaler, J., Halter, B., Machherndl‐Spandl, S., Zebisch, A., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0263-4 · Cited by 40
Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey
Bories, P., Lamy, S., Simand, C., Bertoli, S., Delpierre, C., Malak, S., Fornecker, L., Moreau, S., Récher, C., & Nebout, A. (2018) · Haematologica · doi:10.3324/haematol.2018.192468 · Cited by 42
Is the overall survival for older adults with AML finally improving?
Lancet, J. E. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.09.005 · Cited by 40
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy
Erba, H. P. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.11.027 · Cited by 40
Drug Repurposing for the Treatment of Acute Myeloid Leukemia
Andresen, V., & Gjertsen, B. T. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00211 · Cited by 40
Challenges in Treating Older Patients with Acute Myeloid Leukemia
Lagadinou, E. D., Nicholas, Z. C., & Spyridonidis, A. (2010) · Journal of Oncology · doi:10.1155/2010/943823 · Cited by 39
Targeted therapy in acute myeloid leukaemia: current status and future directions
Stapnes, C., Gjertsen, B. T., Reikvam, H., & Bruserud, Ø. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220902787628 · Cited by 38
Management of Acute Myeloid Leukemia (AML) in Older Patients
Abdallah, M. M., Xie, Z., Ready, A., Manogna, D., Mendler, J. H., & Loh, K. P. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00964-1 · Cited by 38
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy
Wei, A. H., Panayiotidis, P. G., Montesinos, P., Laribi, K., Ivanov, V., Kim, I., Novák, J., Stevens, D. A., Fiedler, W., Pagoni, M. N., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00555-8 · Cited by 38
A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia
Burnett, A. K., Russell, N. H., Hills, R. K., Panoskaltsis, N., Khwaja, A., Hemmaway, C. J., Cahalin, P. A., Clark, R. E., & Milligan, D. W. (2015) · Leukemia · doi:10.1038/leu.2015.38 · Cited by 37
Self-citation
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
Pratz, K. W., Panayiotidis, P. G., Récher, C., Wei, X., Jonas, B. A., Montesinos, P., Ivanov, V., Schuh, A. C., Dinardo, C. D., Novák, J., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00668-8 · Cited by 37
Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions
Short, N. J., & Kantarjian, H. M. (2022) · American Journal of Hematology · doi:10.1002/ajh.26667 · Cited by 37
BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond
Wei, A. H., & Roberts, A. W. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000912 · Cited by 37
Acute myeloid leukemia in the elderly: do we know who should be treated and how?
Nazha, A., & Ravandi, F. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.828348 · Cited by 36
How good are we at predicting the fate of someone with acute myeloid leukaemia?
Estey, E. H., & Gale, R. P. (2017) · Leukemia · doi:10.1038/leu.2017.56 · Cited by 36
A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia
Tsai, D. E., Luger, S. M., Andreadis, C. B., Vogl, D. T., Kemner, A., Potuzak, M., Goradia, A., Loren, A. W., Perl, A. E., Schuster, S. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5185 · Cited by 36
Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
Ferrara, F. (2013) · Hematological Oncology · doi:10.1002/hon.2046 · Cited by 34

Authors: Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K.
Affiliations: Cardiff University (GB)
Heartlands Hospital (GB)
Derriford Hospital (GB)
University College Hospital (GB)
Belfast City Hospital (GB)
Cancer Research UK Clinical Trials Unit (GB)
Corresponding author: Burnett, Alan K.
ORCID: Burnett, Alan K.
Goldstone, Anthony H.
McMullin, Mary F.
Hills, Robert K.
Wheatley, Keith
Venue: Cancer
Publisher: Wiley
Published: 2007-02-21
Volume: 109
Issue: 6
Pages: 1114-1124
ISSN: 0008-543X (ISSN-L)
1097-0142
DOI: 10.1002/cncr.22496
OpenAlex: W2068556430
Cited by: 619
References: 26
Citations by year: 2026: 5 · 2025: 14 · 2024: 13 · 2023: 23 · 2022: 28 · 2021: 43 · 2020: 45 · 2019: 40 · 2018: 29 · 2017: 37 · 2016: 36 · 2015: 54 · 2014: 48 · 2013: 42 · 2012: 36
FWCI: 18.95
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer (publishedVersion)
PubMed (publishedVersion)
ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Research Portal (Queen's University Belfast) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords: acute myeloid leukemia, high-risk myelodysplastic syndrome, low-dose cytarabine, hydroxyurea, all-trans retinoic acid, elderly patients, complete remission, overall survival, adverse cytogenetics, best supportive care
MeSH terms: Acute Disease, Aged, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Female, Humans, Hydroxyurea, Leukemia, Myeloid, Male, Middle Aged, Myelodysplastic Syndromes, Risk, Survival, Tretinoin, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks